Drugs / AGS67E
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02610062 | Mar 2016 → Sep 2017 | acute myeloid leukemia | Astellas Pharma Global Development, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02175433 | Oct 2014 → Oct 2019 | lymphoid hemopathy | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGS67E | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02610062 ↗ |
| Route | Intravenous | “single 30 minute intravenous (IV) infusion of AGS67E once every three weeks” NCT02175433 ↗ |